Due to IDO1’s moonlighting feature (12), the non-enzymatic conformation of the protein plays a relevant, cell-specific role that must be considered when developing candidate drugs that have to target IDO1 in the TME populated by both tumor and immune cells. This evidence concerns the gene IDO1 and neoplasm.